A Neurobiological Investigation of Patients With Schizophrenia Spectrum Disorders and Their Siblings

National Institute of Mental Health (NIMH)1 个研究点分布在 1 个国家目标入组 4,914 人1995年7月15日

适应症Schizoaffective Disorder Schizophrenia

概览

阶段: 不适用
干预措施: Parents
疾病 / 适应症: Schizoaffective Disorder
发起方: National Institute of Mental Health (NIMH)
入组人数: 4914
试验地点: 1
主要终点: Genetic Polymorphisms affect phenotypes
状态: 已完成
最后更新: 4天前

概览研究者入排标准研究组 & 干预措施结局指标研究点相似试验

概览

简要总结

This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.

详细描述

Objective: Schizophrenia is a complex genetic disorder which likely involves many genes each producing a slight increase in risk. Finding weak-acting genes in complex genetic disorders has been challenging and will likely require a number of approaches and large clinical samples. Several strategies have emerged recently that appear to markedly improve the power of genetic studies for detecting such genes. These include using association (rather than linkage) and using intermediate phenotypes in addition to DMS-IV diagnosis. Study Population: We propose to take advantage of these techniques by studying quantitative traits related to schizophrenia in patients, siblings, and controls. Design: We will employ an association design, rather than linkage. Traits will include quantifiable neurobiological variables that have been implicated previously as possible phenotypes related to schizophrenia. These include tests of attention and cognition. Outcome Measure: We will use several statistical methods to show that specific genetic polymorphisms affect these phenotypes, including case control and family based association studies.

注册库

clinicaltrials.gov

开始日期

1995年7月15日

结束日期

待定

最后更新

4天前

研究类型

Observational

性别

All

研究者

发起方

National Institute of Mental Health (NIMH)

责任方

Sponsor

入排标准

入选标准

•INCLUSION/

排除标准

•Inclusion criteria for Siblings (probands and unaffected siblings):
•Probands must have a DSM IV-R diagnosis of schizophrenia,schizoaffective disorder, psychosis N.O.S. or schizophreniform disorder.
•Probands and Siblings must be between the ages of 18 and 55
•Probands and Siblings must be free of major medical illnesses, but may have controlled hypertension, thyroid disease, or diabetes.
•Probands and Siblings must have the cognitive ability to consent for themselves. Those who are judged to have the cognitive ability to consent for themselves at the time of participation, but do not have the legal capacity to consent for themselves may participate if the legal guardian /Legal authorized representative (LAR) provides consent by signing the informed consent form.
•Fluency in English is required.
•Exclusion Criteria for Siblings (probands and unaffected siblings):
•Seizure disorder, mental retardation, organic brain damage or other neurological disease.
•History of any (excepting nicotine-related) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence).
•Cumulative lifetime history of any (excepting nicotine-related) DSM5-defined mild substance use disorder (or any DSM-IV-defined substance abuse), either in excess of 5 years total or not in remission for at least 6 months.